tiprankstipranks
Trending News
More News >
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
US Market
Advertisement

scPharmaceuticals (SCPH) AI Stock Analysis

Compare
506 Followers

Top Page

SCPH

scPharmaceuticals

(NASDAQ:SCPH)

Rating:59Neutral
Price Target:
$6.00
▲(7.72% Upside)
scPharmaceuticals' overall stock score is primarily impacted by its financial instability, with high debt levels and negative cash flows posing significant risks. However, strong technical indicators and positive strategic developments, such as the merger with MannKind Corporation, provide a counterbalance, suggesting potential for future growth. The earnings call further supports optimism with robust revenue growth and strategic advancements, despite ongoing cost challenges.
Positive Factors
Cost Efficiency
The autoinjector could reduce costs associated with Furoscix by 70-75%, indicating potential for increased efficiency.
Market Adoption
The rapid adoption of Furoscix in chronic kidney disease among nephrologists suggests a strong market acceptance.
Negative Factors
Acquisition Interest
No additional bidders are expected, suggesting limited competitive interest in acquiring scPharmaceuticals beyond the current agreement with MannKind.
Downgrade in Recommendation
Analyst downgrades scPharmaceuticals shares to Hold from Buy, reflecting a cautious stance on future stock price appreciation.

scPharmaceuticals (SCPH) vs. SPDR S&P 500 ETF (SPY)

scPharmaceuticals Business Overview & Revenue Model

Company DescriptionscPharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products that utilize its proprietary subcutaneous drug delivery technology. The company operates primarily in the healthcare sector, with a core focus on providing treatments for patients with chronic conditions, particularly in the areas of heart failure and other serious illnesses. scPharmaceuticals aims to enhance patient outcomes and improve the convenience of administering medications through its products, which include its lead product candidate, Furoscix, a subcutaneous formulation of furosemide for the treatment of worsening heart failure.
How the Company Makes MoneyscPharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, particularly Furoscix, once it receives regulatory approval. The company's revenue model includes direct sales of its products to healthcare providers and patients. Additionally, scPharmaceuticals may engage in partnerships and collaborations with other pharmaceutical companies or healthcare organizations, which can provide upfront payments, milestone payments, and royalties based on product sales. These strategic partnerships can enhance the company's financial stability and expand its market reach. The company may also explore licensing agreements that allow other entities to develop or market its products, further contributing to its revenue streams.

scPharmaceuticals Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call reflected strong revenue and dosage growth, successful launches, and strategic positioning for future growth through regulatory and market dynamics. However, increased costs and cash flow challenges were noted, along with uncertainties in IDN fulfillment rates.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
scPharmaceuticals generated $16 million in net revenue for Q2 2025, marking a 99% increase over Q2 2024.
FUROSCIX Doses Increase
Approximately 20,200 FUROSCIX doses were filled, representing a 117% increase over Q2 2024 and a 45% increase over Q1 2025.
Nephrology Launch Success
The nephrology launch of FUROSCIX showed faster adoption rates by nephrologists compared to cardiologists, with higher doses per prescription.
IDN Business Growth
The Integrated Delivery Network (IDN) business grew by 70% quarter-over-quarter, becoming a significant part of total sales.
Positive Impact of Medicare Part D Dynamics
An increasing number of Part D patients reached their out-of-pocket maximums, positively impacting Q2 performance and expected to enhance future market penetration.
Regulatory and Strategic Advancements
The anticipated submission of the SNDA for the auto-injector and the CMS proposed ambulatory specialty model are expected to provide future growth opportunities.
Negative Updates
Increased Costs and Cash Flow Challenges
The cost of product revenues increased to $5 million in Q2 2025 from $2.3 million in Q2 2024, and cash and cash equivalents decreased from $75.5 million at the end of 2024 to $40.8 million at the end of Q2 2025.
Uncertainty in IDN Fulfillment Rates
Despite growth, there is a lack of clear visibility on fill rates in the IDN segment, complicating performance assessment.
Company Guidance
During the scPharmaceuticals' Second Quarter 2025 Earnings Conference Call, key metrics and guidance were provided, indicating robust growth and strategic advancements. The company reported $16 million in net revenue for Q2 2025, marking a 99% increase compared to Q2 2024. Approximately 20,200 FUROSCIX doses were filled, representing a 117% increase over the previous year and a 45% increase from Q1 2025. The growth was largely driven by cardiology, with nephrology starting to contribute following the launch into this area in late April. The company highlighted the anticipated impact of the Medicare Part D redesign, which is expected to continue enhancing market penetration as more patients reach their out-of-pocket maximums. Additionally, scPharmaceuticals is on track to submit a supplemental new drug application (SNDA) for an auto-injector in Q3 2025, which could result in a 75% reduction in cost of goods sold (COGS) and increased penetration rates. The company ended Q2 with $40.8 million in cash, down from $75.5 million at the end of 2024, but expects cash flows to improve with increasing revenues and a recent price increase. Overall, scPharmaceuticals expressed optimism about the future growth prospects of FUROSCIX, driven by favorable market dynamics and strategic initiatives.

scPharmaceuticals Financial Statement Overview

Summary
scPharmaceuticals shows promising revenue growth, yet faces significant challenges in profitability, leverage, and cash flow. The company's high debt levels and negative equity position indicate financial instability, while negative cash flows suggest ongoing operational difficulties. Continued focus on improving operational efficiency and financial health is essential for future stability and growth.
Income Statement
45
Neutral
The company demonstrated a significant increase in revenue from 2023 to 2024, showing positive growth potential. However, profitability remains a concern, with consistent net losses and negative EBIT and EBITDA margins, indicating challenges in achieving operational efficiency and profitability.
Balance Sheet
30
Negative
The balance sheet reflects a high debt-to-equity ratio, indicating significant leverage and potential financial risk. Negative stockholders' equity is a concern, suggesting liabilities exceed assets, which may pose financial stability risks. The equity ratio is negative, highlighting the company's reliance on debt financing.
Cash Flow
35
Negative
Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow is also negative, indicating cash outflows exceed cash inflows, which may impact the company's ability to fund operations and growth without external financing.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue49.97M36.33M13.59M0.000.000.00
Gross Profit34.21M24.97M9.78M-468.00K-438.00K-399.00K
EBITDA-82.60M-77.43M-46.06M-33.07M-25.02M-29.22M
Net Income-91.72M-85.15M-54.81M-36.84M-28.03M-32.21M
Balance Sheet
Total Assets80.25M107.52M94.48M124.19M79.04M109.05M
Cash, Cash Equivalents and Short-Term Investments40.81M75.66M76.01M118.37M75.46M105.28M
Total Debt52.45M52.69M40.27M37.37M17.64M20.21M
Total Liabilities101.57M94.20M57.26M51.76M22.57M26.88M
Stockholders Equity-21.32M13.32M37.22M72.43M56.47M82.17M
Cash Flow
Free Cash Flow-65.88M-70.56M-59.28M-34.60M-27.16M-27.69M
Operating Cash Flow-65.86M-70.54M-59.24M-34.58M-27.15M-27.69M
Investing Cash Flow-21.00K29.30M19.96M-45.86M32.13M-33.46M
Financing Cash Flow68.19M70.08M14.85M77.23M-2.53M60.35M

scPharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.57
Price Trends
50DMA
4.87
Positive
100DMA
4.04
Positive
200DMA
3.63
Positive
Market Momentum
MACD
0.20
Negative
RSI
63.11
Neutral
STOCH
84.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCPH, the sentiment is Positive. The current price of 5.57 is above the 20-day moving average (MA) of 5.06, above the 50-day MA of 4.87, and above the 200-day MA of 3.63, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 63.11 is Neutral, neither overbought nor oversold. The STOCH value of 84.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCPH.

scPharmaceuticals Risk Analysis

scPharmaceuticals disclosed 70 risk factors in its most recent earnings report. scPharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

scPharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$297.40M-934.02%107.79%-16.01%
57
Neutral
$230.63M-77.51%-21.09%90.95%
56
Neutral
$684.29M-440.80%-19.56%35.55%
52
Neutral
44.85%
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
49
Neutral
$320.35M-60.25%-40.03%
35
Underperform
$451.63M-140.33%-0.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SCPH
scPharmaceuticals
5.57
0.52
10.30%
NKTR
Nektar Therapeutics
40.18
22.48
127.01%
RGLS
Regulus
8.16
6.65
440.40%
TNXP
Tonix Pharma
26.54
10.03
60.75%
LRMR
Larimar Therapeutics
3.94
-3.60
-47.75%
KOD
Kodiak Sciences
10.52
8.14
342.02%

scPharmaceuticals Corporate Events

M&A TransactionsBusiness Operations and Strategy
scPharmaceuticals Announces Merger with MannKind Corporation
Positive
Aug 25, 2025

On August 24, 2025, scPharmaceuticals entered into a merger agreement with MannKind Corporation, which will acquire all outstanding shares of scPharmaceuticals through a tender offer. The acquisition, valued at up to $360 million, aims to diversify and accelerate MannKind’s revenue growth, particularly with FUROSCIX, and strengthen its position in the cardiometabolic and lung disease sectors. The merger is expected to close in the fourth quarter of 2025, subject to regulatory approvals and customary conditions. This strategic move is anticipated to enhance MannKind’s market reach and integrate scPharmaceuticals’ commercial capabilities into its existing infrastructure.

Product-Related AnnouncementsBusiness Operations and Strategy
scPharmaceuticals Extends SmartDose Supply Agreement
Neutral
Aug 25, 2025

On August 20, 2025, scPharmaceuticals Inc. amended its supply agreement with West Pharmaceutical Services, Inc. for the SmartDose® drug delivery system, extending the agreement’s term until December 31, 2027. The amendment outlines the company’s financial responsibilities upon termination, impacting its operational commitments and strategic partnerships in the drug delivery market.

Executive/Board ChangesShareholder Meetings
scPharmaceuticals Holds Annual Stockholders Meeting June 2025
Neutral
Jun 9, 2025

On June 3, 2025, scPharmaceuticals Inc. held its Annual Meeting of Stockholders, with 35,156,523 shares represented, accounting for approximately 69.91% of the company’s outstanding common stock. During the meeting, William T. Abraham, M.D., Mette Kirstine Agger, and Minnie Baylor-Henry were elected as Class II Directors, and the appointment of RSM US LLP as the independent registered public accounting firm was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 26, 2025